Natera (NTRA) News
NASDAQ: NTRAHealth CareMedical SpecialitiesUSD
400.71+9.92 (+2.54%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NTRA news summary
We found 36 recent headlines mentioning Natera (NTRA): 2 in the past week and 13 in the past 30 days, most often from Seeking Alpha, Nasdaq. For price context, NTRA is up 2.54% at $400.71. The most recent story, "Natera's Multi-cancer Early Detection Assay Granted Breakthrough Device Designation By FDA", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Natera headlines
- Natera's Multi-cancer Early Detection Assay Granted Breakthrough Device Designation By FDA(RTTNews) - Natera, Inc. (NTRA), a cell-free DNA and precision medicine company, announced Friday that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation…Nasdaq
- Natera: Priced To Perfection Amidst Rising Competitive ThreatsSeeking Alpha
- iShares Biotechnology ETF Experiences Big InflowLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Biotechnology ETF (Symbol: IBB) where we have detected an…NasdaqIBB, REGN, NTRA, ARGX
- Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDxNTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.NasdaqNTRA, ISRG, GMED, VCYT
- Notable ETF Outflow Detected - XBI, TWST, HALO, NTRALooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR S&P Biotech ETF (Symbol: XBI) where we have…NasdaqXBI, TWST, HALO, NTRA
- Natera Announces Japan's PMDA Authorization For Signatera In Muscle-Invasive Bladder Cancer(RTTNews) - Natera, Inc. (NTRA) announced that its Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency as a companion diagnostic in muscle-invasive…Nasdaq
- Natera, Inc. (NTRA) Presents at 2026 Global Healthcare Conference TranscriptSeeking Alpha
- Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaNTRA, MS
- Natera CEO Steven Chapman Sells 1,698 Shares for $545,000Key PointsThe disposal represented 2% of the total equity stake held by the executive prior to the transaction.Nasdaq
- Show Me The Money: Natera Delivers Over 120% Gain In Just About A Year(RTTNews) - For Natera Inc. (NTRA), the journey so far has been nothing short of remarkable, with its shares scaling new heights to reach an all-time high of $366.70 yesterday.Nasdaq
- NTRA Crosses Above Average Analyst TargetIn recent trading, shares of Natera Inc (Symbol: NTRA) have crossed above the average analyst 12-month target price of $339.79, changing hands for $341.72/share. When a stock reaches the target an…Nasdaq
- This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy?Key PointsInstead, it's -- of all things -- a medical diagnostics company.Nasdaq
- State Street SPDR S&P Biotech ETF Experiences Big OutflowLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR S&P Biotech ETF (Symbol: XBI) where we have…NasdaqXBI, TWST, HALO, NTRA
- Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia)Key PointsStanley Druckemiller holds some smaller positions in Amazon and Alphabet.NasdaqNTRA, NVDA
- Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?Key PointsNatera ranks as the top holding in Druckenmiller's Duquesne Family Office portfolio.Nasdaq
- Natera & Angiex Partner to Evaluate AGX101 Response With SignateraNTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.NasdaqNTRA, WST, GMED, VCYT
- Notable ETF Outflow Detected - JGRO, NTRA, PWR, DELooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the JPMorgan Active Growth ETF (Symbol: JGRO) where we have detected an…NasdaqJGRO, NTRA, PWR, DE
- Natera And Angiex Partners To Advance Response Monitoring In Solid Tumors(RTTNews) - Natera, Inc. (NTRA), a company specializing in cell-free DNA and precision medicine, has announced a collaboration with Angiex, Inc., a privately held biotech company developing…Nasdaq
- Natera Partners With Angiex For CtDNA Monitoring In Solid Tumor Trial Using Signatera(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company announced on Thursday that it will collaborate with privately held Angiex, Inc., to use its Signatera test for circulating tumor…Nasdaq
- Natera: The Growth May Not Justify Current LevelsSeeking Alpha
- Natera: Even 30% Annual Growth Through 2030 Doesn't Support $310 Per ShareSeeking Alpha
- Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference TranscriptSeeking Alpha
- Natera outlines $2.85B-$2.91B 2026 revenue outlook backed by 31% growth ex true-upsSeeking Alpha
- Natera, Inc. (NTRA) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Natera, Inc. 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha
- After-Hours Earnings Report for August 6, 2026 : NET, MNST, AFL, ABNB, RSG, WPM, SLF, AIG, MCHP, ED, NTRA, RMDThe following companies are expected to report earnings after hours on 08/06/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Cloudflare, Inc. (NET)is reporting for the…NasdaqNET, MNST, AFL, ABNB
- Natera: All-Time Share Price High A Potential Caveat For Investors, Despite PromiseSeeking Alpha
- Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking AlphaNTRA, GS
- Natera: A Growing Biotech, After Recent FDA Approval And Q1 Revenue ResultsSeeking Alpha
- Natera, Inc. (NTRA) Q1 2026 Earnings Call TranscriptSeeking Alpha
- Natera, Inc. 2026 Q1 - Results - Earnings Call PresentationSeeking Alpha
- Natera Looks Compelling As Oncology Testing Momentum Keeps BuildingSeeking Alpha
- Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference TranscriptSeeking Alpha
- Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha
- Natera, Inc. 2025 Q4 - Results - Earnings Call PresentationSeeking Alpha